Schrödinger, Inc. (NASDAQ:SDGR) Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. grew its stake in Schrödinger, Inc. (NASDAQ:SDGR) by 5.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 24,519 shares of the company’s stock after purchasing an additional 1,278 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Schrödinger were worth $878,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Spire Wealth Management raised its stake in shares of Schrödinger by 66.7% in the 3rd quarter. Spire Wealth Management now owns 1,000 shares of the company’s stock valued at $28,000 after purchasing an additional 400 shares in the last quarter. International Assets Investment Management LLC raised its stake in shares of Schrödinger by 3,480.0% in the 4th quarter. International Assets Investment Management LLC now owns 1,790 shares of the company’s stock valued at $64,000 after purchasing an additional 1,740 shares in the last quarter. National Bank of Canada FI raised its stake in shares of Schrödinger by 260.0% in the 3rd quarter. National Bank of Canada FI now owns 1,800 shares of the company’s stock valued at $49,000 after purchasing an additional 1,300 shares in the last quarter. Exchange Traded Concepts LLC grew its position in shares of Schrödinger by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 4,244 shares of the company’s stock valued at $152,000 after buying an additional 1,076 shares during the last quarter. Finally, SG Americas Securities LLC grew its position in shares of Schrödinger by 23.4% during the 3rd quarter. SG Americas Securities LLC now owns 4,728 shares of the company’s stock valued at $134,000 after buying an additional 896 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Schrödinger Trading Up 1.3 %

NASDAQ SDGR opened at $24.81 on Wednesday. Schrödinger, Inc. has a 52 week low of $20.76 and a 52 week high of $59.24. The stock has a market cap of $1.79 billion, a price-to-earnings ratio of 39.38 and a beta of 1.57. The company has a 50-day moving average price of $27.15 and a two-hundred day moving average price of $28.34.

Schrödinger (NASDAQ:SDGR) last posted its earnings results on Wednesday, February 28th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.12. Schrödinger had a net margin of 18.79% and a negative return on equity of 23.58%. The firm had revenue of $74.10 million during the quarter, compared to analysts’ expectations of $79.12 million. During the same quarter in the prior year, the firm earned ($0.39) EPS. Schrödinger’s quarterly revenue was up 30.5% on a year-over-year basis. As a group, equities research analysts expect that Schrödinger, Inc. will post -2.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on SDGR. Craig Hallum lowered their price objective on shares of Schrödinger from $40.00 to $35.00 and set a “buy” rating for the company in a research report on Friday, January 19th. Piper Sandler lowered their price objective on shares of Schrödinger from $60.00 to $50.00 and set an “overweight” rating for the company in a research report on Thursday, February 29th. Bank of America lowered their price objective on shares of Schrödinger from $38.00 to $32.00 and set a “neutral” rating for the company in a research report on Thursday, February 29th. Citigroup lowered their price objective on shares of Schrödinger from $47.00 to $39.00 and set a “buy” rating for the company in a research report on Thursday, February 29th. Finally, The Goldman Sachs Group lowered their price objective on shares of Schrödinger from $29.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, March 1st. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $43.50.

Insider Activity

In other news, insider Robert Lorne Abel sold 1,205 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $27.55, for a total value of $33,197.75. Following the completion of the transaction, the insider now directly owns 9,340 shares in the company, valued at $257,317. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, COO Kenneth Patrick Lorton sold 901 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $28.29, for a total value of $25,489.29. Following the completion of the transaction, the chief operating officer now directly owns 36,487 shares in the company, valued at $1,032,217.23. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Robert Lorne Abel sold 1,205 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $27.55, for a total transaction of $33,197.75. Following the completion of the transaction, the insider now owns 9,340 shares of the company’s stock, valued at $257,317. The disclosure for this sale can be found here. Insiders sold 3,651 shares of company stock worth $102,395 over the last three months. Corporate insiders own 7.60% of the company’s stock.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.